durvalumab,sorafenib,tremelimumab
pfizer,astrazeneca
['tremelimumab', 'aster,70', 'rova,(-approval),(-microvascular)', 'durva', 'hcc', 'cv,202,103', 'sorafenib', 'himalaya']
very nice long term results of stride arm in himalaya trial. single dose of tremelimumab + durva is really effective in uhcc. no difference in subgroup analysis . #wcgic2023 
Oncólogo colombiano. Ayudo a los pacientes con cáncer a resolver algunos de sus problemas. #PrecisionOncology #OncoGI Opiniones personales.